Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00641953
Other study ID # 01-004A
Secondary ID
Status Completed
Phase Phase 2
First received March 17, 2008
Last updated June 13, 2008
Start date August 2007
Est. completion date March 2008

Study information

Verified date June 2008
Source Procris Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effectiveness of two different dose of IMX-150 to that of placebo (non-active) in the treatment of diabetic peripheral neuropathy pain of the feet.


Recruitment information / eligibility

Status Completed
Enrollment 155
Est. completion date March 2008
Est. primary completion date March 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Must have sufficient command and understanding of the English language to complete diaries and questionnaires

- If female, may not be pregnant or lactating

- Can be treated on an outpatient basis

- Has a clinical diagnosis of Type-1 or Type II diabetes with: confirmed diagnosis of diabetic distal symmetrical sensorimotor polyneuropathy and bilateral pain in the feet for at least 3 months.

- Must have a hemoglobin A1C value of 11% or less that is stable under treatment

- Agrees to use the test creams as specified for the 4 week period

- Willing to not use any other medications, including investigational medications, to treat pain symptoms of Diabetic Neuropathy while in study.

Exclusion Criteria:

- Currently using any nitrate medications

- Currently using Viagra®, Levitra®, Cialis® or other phosphodiesterase 5 inhibitors medications for erectile dysfunction

- Currently treated for symptoms of diabetic neuropathy, including but not limited to Lyrica®, Cymbalta® and transcutaneous stimulation

- Not on a stable dose for at least 4 weeks prior to study screening of other vasodilators required for underlying conditions

- Know allergy to Nitroglycerin, propylene glycol or common moisturizing creams

- History of migraine, cluster or vascular headaches, chronic pain with greater pain intensity than the pain of diabetic neuropathy or other chronic pain condition within the region of the diabetic peripheral neuropathy

- Amputation of more than one toe per foot

- Neurological disorder or skin condition that may alter local sensation in the feet

- History of unstable medical problem, clinically significant screening laboratory test or any current medical condition that would contraindicate the administration of the study mediation, interfere with the study evaluations, or interfere with the patient's ability to comply with the study

- History of drug (including cannabinoid) or alcohol abuse within the past year

- Cognitive or language difficulties that would impair completion of the pain assessment tool

- Within the past 3 months, have had either a myocardial infarction, uncontrolled hypotension, or uncontrolled hypertension

- Participated in a study of any investigational drug within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to Screening

- Major abdominal, thoracic or vascular surgery within 6 months of the first dose of study medication

- Open lesions in the area where the cream is to be applied

- Fertile patients who are unable or unwilling to comply with the contraceptive requirements during the study period

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
IMX-150
(0.3%) 0.5g topically BID to each foot for 4 weeks
IMX-150
(0.6%) 0.5g topically BID to each foot for 4 weeks
Placebo
0.5 g topically BID to each foot for 4 weeks

Locations

Country Name City State
United States Meriden Research Brooksville Florida
United States Health Awareness Jupiter Florida
United States International Research Associates, LLC Miami Florida
United States Hampton Roads Center for Clinical Research Norfolk Virginia
United States Peninsula Research Ormond Beach Florida
United States Alpha Medical Research Oviedo Florida
United States Meridien Research Saint Petersburg Florida

Sponsors (1)

Lead Sponsor Collaborator
Procris Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline to endpoint (Day 29) in the average of neuropathic foot daily pain "24 - Hour Average Pain" scores Weekly average of "24-hour Average Pain" No
Secondary Change in weekly average sleep disturbance daily No
See also
  Status Clinical Trial Phase
Recruiting NCT04638556 - Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy
Completed NCT05580705 - Effects of Vibration Therapy in Addition to Routine Physical Therapy in Patients With Diabetic Neuropathy N/A
Terminated NCT01620775 - MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain N/A
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Completed NCT00835757 - Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy N/A
Recruiting NCT00553592 - Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes Phase 2
Recruiting NCT05863793 - Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy N/A
Withdrawn NCT05041816 - Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy N/A
Recruiting NCT06074562 - A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Recruiting NCT04457531 - LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy Early Phase 1
Completed NCT02947828 - Polyneuropathy in Diabetes Mellitus Type 2
Completed NCT02056431 - Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy N/A
Completed NCT01681290 - Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes Phase 2
Completed NCT01474772 - Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN) Phase 3
Completed NCT01086150 - Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy Phase 2/Phase 3
Completed NCT03447756 - Titration Study of ABX-1431 Phase 1
Completed NCT04688671 - Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain Phase 2
Completed NCT04984044 - Effect of Vitamin D in Patients With Diabetic Peripheral Neuropathy to Alleviate Pain and Improvement of Symptoms N/A
Completed NCT06130917 - Effects of Multisystem Exercise on Balance, Postural Stability, Mobility and Pain in Patients With DPN. N/A
Completed NCT01496365 - Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy Phase 2